---

---

results   tags : Liver   

save search

---

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.015 -1.46% -1.48% 120K |

Health Technology

| 1.97% | O: 64.34% H: 4.82% C: -18.67%
fxr314 metabolic liver positive for results

---

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| Email alert Add to watchlist
pharma liver disease fibrosis trial results

---

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 20:00) - prnewswire.com
LPCN | $4.88 -3.75% -3.89% 76K |

Health Technology

| 82.37% | O: -2.52% H: 6.27% C: -0.92%
meeting liver presentation results phase 2

---

CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
CBAY | $32.48 0.03% 8.4M |

Health Technology

| 118.51% | O: 7.07% H: 6.73% C: 6.03%
meeting liver presentation results

---

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 13:30) - globenewswire.com
SGMT | News | $4.27 5.96% 5.62% 360K |

Health Technology

| 43.93% | O: 5.0% H: 0.0% C: -12.07%
meeting liver preclinical potential results

---

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
ALGS | $0.839 4.74% 4.53% 97K |

Health Technology

| 3.9% | O: 0.0% H: 1.3% C: -9.26%
alg-0001 meeting hepatitis liver alg-000184 positive treatment therapeutics results

---

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Published: 2023-10-10 (Crawled : 11:00) - globenewswire.com
AKRO | $21.02 1.11% 1.09% 560K |

Health Technology

| -57.17% | O: -59.06% H: 0.0% C: -8.66%
liver fibrosis therapeutics results insulin nash

---

Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
Published: 2023-10-05 (Crawled : 12:00) - biospace.com/
BTTX | $0.0061 -65.02% 300K |

| -97.1% | O: 1.13% H: 5.96% C: -7.68%
liver disease publication therapeutics results study

---

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Published: 2023-06-30 (Crawled : 05:00) - globenewswire.com
GNFT | $3.44 -6.01% -6.4% 2.2K |

Health Technology

| -9.63% | O: 0.0% H: 0.99% C: -12.59%
elative rare liver disease positive trial results

---

Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-05-19 (Crawled : 20:00) - globenewswire.com
HEPA | $1.47 4.26% 4.08% 71K |

Health Technology

| Email alert Add to watchlist
liver conference review pharmaceuticals topline trial results phase 2

---

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -14.25% | O: 0.13% H: 0.38% C: -0.19%
ARWR | $23.775 -0.61% -0.61% 830K |

Health Technology

| -36.01% | O: -19.61% H: 3.16% C: 0.77%
liver disease topline results study

---

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
Published: 2023-01-06 (Crawled : 13:20) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K |

Health Technology

| -21.43% | O: 0.18% H: 3.75% C: 3.28%
treatment fibrosis liver trial positive nash

---

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
CMMB | $0.66 0.02% 0.02% 7.2K |

Manufacturing

| -79.38% | O: 50.31% H: 11.23% C: -38.88%
cm-101 fibrosis liver biomarker trial results nash phase 2b

---

Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Published: 2022-12-20 (Crawled : 12:20) - globenewswire.com
ALT | $7.56 1.21% 1.19% 3.1M |

Commercial Services

| -27.19% | O: -4.19% H: 21.16% C: 21.06%
liver disease topline trial positive results

---

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDGL | $218.17 2.19% 2.15% 410K |

Health Technology

| 234.62% | O: 219.37% H: 0.0% C: 0.0%
treatment fibrosis liver topline trial positive nash

---

Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
Published: 2022-12-08 (Crawled : 12:20) - biospace.com/
BTTX | $0.0061 -65.02% 300K |

| -99.3% | O: -1.41% H: 8.56% C: 3.59%
liver disease topline trial therapeutics positive

---

GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
Published: 2022-10-25 (Crawled : 21:00) - globenewswire.com
GNFT | $3.44 -6.01% -6.4% 2.2K |

Health Technology

| -12.44% | O: -2.39% H: 2.94% C: -1.72%
meeting liver diagnostic technology nash

---

Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022 POXEL SA announced that its late-breaking abstract describing the results from its Phase 2 study of PXL065...
Published: 2022-10-12 (Crawled : 07:00) - biospace.com/
NKTR | News | $1.415 4.04% 3.89% 1.1M |

Health Technology

| -61.8% | O: -1.69% H: 3.29% C: 0.57%
pxl065 meeting liver nash study phase 2

---

Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
Published: 2022-06-27 (Crawled : 23:00) - biospace.com/
EIGR | $1.725 -1.45% 140K |

Health Technology

| -72.36% | O: 0.96% H: 3.97% C: 2.06%
liver international

---

Telos Corporation Announces Fourth Quarter Results: Delivers 43% Sales Growth and Expands Gross Margin 196 Basis Points; Issues 2022 Guidance
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
TLS | $3.43 2.7% 2.62% 240K |

Technology Services

| -65.64% | O: -6.69% H: 0.0% C: 0.0%
sales liver corporation results growth

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---